Fig. 1.

Patient identification and attrition. ^aMedical data were defined as clinical data in the patient record from outpatient physician office visits, non-facility visits, laboratory visits, treatment/procedure visits or medication administration. Patients who died within 1 month were not excluded. ^bThe following therapies were excluded: atezolizumab, avelumab, durvalumab, ipilimumab, nivolumab, pembrolizumab and trastuzumab. Adv/met unresectable locally advanced, recurrent or metastatic, EC esophageal cancer, ESCC esophageal squamous cell carcinoma, GC gastric cancer, GEJC gastroesophageal junction cancer